美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Aardvark Therapeutics

5.13

+0.12002.40%

盤後：5.130.00000.00%19:30 EDT

成交量：27.66萬

成交額：142.61萬

市值：1.11億

市盈率：-1.60

高：5.54

開：5.11

低：4.98

收：5.01

52周最高：17.94

52周最低：3.35

股本：2,169.69萬

流通股本：1,116.83萬

量比：1.66

換手率：2.48%

股息：- -

股息率：- -

每股收益(TTM):-3.2080

每股收益(LYR):-0.7400

淨資產收益率：-66.02%

總資產收益率：-40.38%

市淨率：1.49

市盈率(LYR):-6.93

資料載入中...

總覽公司新聞公告

熱門話題-FDA對一種罕見病藥物下達臨床暫停令後，Aardvark股價重挫

FDA對Aardvark治療普拉德-威利綜合徵極度飢餓藥物下達全面臨床暫停令

Aardvark Therapeutics將揭盲Ard-101的HERO與OLE試驗數據以進行評估，並確定該項目的後續計劃

Aardvark Therapeutics 計劃揭盲HERO與OLE研究數據，為FDA臨床擱置後的前行之路提供指引

美國研究綜述-亞馬遜、Diamondback Energy、Matador Resources

Aardvark Therapeutics與Piper Sandler簽訂股權分銷協議，於2026年3月23日提交SEC文件

Aardvark 在審查副作用時暫停兩項肥胖症藥物試驗

Aardvark Therapeutics暫停針對PWS的Ard-101三期HERO及OLE試驗；最新指引預計2026年第二季度公布

Aardvark Therapeutics暫停Ard-201肥胖症項目，包括力量與體能試驗；進一步指引預計2026年第二季度公布

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/AARD/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"AARD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","market":"US","secType":"STK","nameCN":"Aardvark Therapeutics","latestPrice":5.13,"timestamp":1789156800000,"preClose":5.01,"halted":0,"volume":276570,"hourTrading":{"tag":"盘后","latestPrice":5.13,"preClose":5.13,"latestTime":"19:30 EDT","volume":206,"amount":1046.1438,"timestamp":1789169407266,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.023952095808383256,"floatShares":11168300,"shares":21696893,"eps":-3.207951,"marketStatus":"休市中","change":0.12,"latestTime":"09-11 16:00:00 EDT","open":5.11,"high":5.54,"low":4.975,"amount":1426131.82215,"amplitude":0.112774,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.207951,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1739509200000,"exchange":"NASDAQ","adjPreClose":5.01,"preHourTrading":{"tag":"盘前","latestPrice":5.13,"preClose":5.01,"latestTime":"09:29 EDT","volume":2158,"amount":11042.7393492,"timestamp":1789133399999,"change":0.12,"changeRate":0.023952,"amplitude":0.164112},"postHourTrading":{"tag":"盘后","latestPrice":5.13,"preClose":5.13,"latestTime":"19:30 EDT","volume":206,"amount":1046.1438,"timestamp":1789169407266,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.6636650076334776,"impliedVol":1.0917,"impliedVolPercentile":0.3975},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","floatShares":11168300,"roa":"-40.38%","roe":"-66.02%","lyrEps":-0.74,"volumeRatio":1.6636650076334776,"shares":21696893,"dividePrice":0,"high":5.54,"amplitude":0.112774,"preClose":5.01,"low":4.975,"week52Low":3.35,"pbRate":"1.49","week52High":17.94,"institutionHeld":0,"latestPrice":5.13,"eps":-3.207951,"divideRate":0,"volume":276570,"delay":0,"ttmEps":-3.207951,"open":5.11,"prevYearClose":13.125,"prevWeekClose":5.38,"prevMonthClose":6.1,"prevQuarterClose":5.76,"fiveDayClose":5.73,"twentyDayClose":6.41,"sixtyDayClose":3.72},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AARD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"AARD","fiscalQuarterEnding":"2026/06","expectedEps":-0.87,"name":null,"time":"盤後","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2026-05-07","symbol":"AARD","fiscalQuarterEnding":"2026/03","expectedEps":-0.81,"name":null,"time":"盤前","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-0.99},{"market":"US","date":"2026-03-23","symbol":"AARD","fiscalQuarterEnding":"2025/12","expectedEps":-0.81,"name":null,"time":"盤後","type":"earning","dateTimestamp":1774238400000,"reportTimeType":"post","actualEps":-0.81},{"market":"US","date":"2025-11-13","symbol":"AARD","fiscalQuarterEnding":"2025/09","expectedEps":-0.82,"name":null,"time":"盤後","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.75},{"market":"US","date":"2025-08-13","symbol":"AARD","fiscalQuarterEnding":"2025/06","expectedEps":-0.52,"name":null,"time":"盤後","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.66}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AARD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AARD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AARD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AARD","date":"2026-09-11","current":-1.599152,"percent":0.887755,"low":-51.17654,"twenty":-9.389042,"median":-6.017873,"eighty":-1.978384,"high":-1.08662,"avg":-7.626575,"sd":8.299905,"marketCap":109643078},"quantilePoints":[{"date":"2025-02-21","current":-51.17654,"twenty":-46.993414,"median":-42.216938,"eighty":-39.920668,"marketCap":368880503},{"date":"2025-02-28","current":-39.75453,"twenty":-42.139802,"median":-40.229211,"eighty":-39.232381,"marketCap":286550651},{"date":"2025-03-07","current":-28.243517,"twenty":-40.603022,"median":-39.176012,"eighty":-36.900511,"marketCap":203579269},{"date":"2025-03-14","current":-31.091602,"twenty":-40.336014,"median":-37.766803,"eighty":-30.723725,"marketCap":224108270},{"date":"2025-03-21","current":-27.23482,"twenty":-39.944402,"median":-34.681377,"eighty":-29.198812,"marketCap":196308580},{"date":"2025-03-28","current":-26.404128,"twenty":-39.576524,"median":-30.913597,"eighty":-27.946841,"marketCap":190320955},{"date":"2025-04-04","current":-9.026143,"twenty":-39.119644,"median":-30.068072,"eighty":-27.341623,"marketCap":185830236},{"date":"2025-04-11","current":-7.397773,"twenty":-38.751766,"median":-29.400552,"eighty":-17.252871,"marketCap":152305358},{"date":"2025-04-17","current":-7.977371,"twenty":-38.300819,"median":-28.45119,"eighty":-8.603741,"marketCap":164238114},{"date":"2025-04-25","current":-8.66235,"twenty":-37.766803,"median":-27.946841,"eighty":-8.371497,"marketCap":178340462},{"date":"2025-05-02","current":-11.939711,"twenty":-36.900511,"median":-27.412825,"eighty":-8.371497,"marketCap":245814773},{"date":"2025-05-09","current":-11.307423,"twenty":-34.865316,"median":-26.68597,"eighty":-8.46634,"marketCap":232797221},{"date":"2025-05-16","current":-7.114571,"twenty":-32.693651,"median":-13.552046,"eighty":-8.46634,"marketCap":197215912},{"date":"2025-05-23","current":-7.834638,"twenty":-31.0204,"median":-11.823792,"eighty":-8.360959,"marketCap":217176159},{"date":"2025-05-30","current":-8.061615,"twenty":-30.818661,"median":-11.433881,"eighty":-8.172533,"marketCap":223467976},{"date":"2025-06-06","current":-9.353039,"twenty":-30.367714,"median":-11.107198,"eighty":-8.178795,"marketCap":259266244},{"date":"2025-06-13","current":-8.656453,"twenty":-30.076972,"median":-10.833207,"eighty":-8.210998,"marketCap":239956875},{"date":"2025-06-20","current":-9.454788,"twenty":-30.053238,"median":-10.188135,"eighty":-8.218152,"marketCap":262086713},{"date":"2025-06-27","current":-10.84796,"twenty":-29.697227,"median":-10.664596,"eighty":-8.356744,"marketCap":300705451},{"date":"2025-07-03","current":-10.894921,"twenty":-29.459887,"median":-10.613156,"eighty":-8.365174,"marketCap":302007206},{"date":"2025-07-11","current":-9.861782,"twenty":-29.308323,"median":-10.597502,"eighty":-8.375712,"marketCap":273368592},{"date":"2025-07-18","current":-9.360866,"twenty":-28.618005,"median":-10.433139,"eighty":-8.40036,"marketCap":259483203},{"date":"2025-07-25","current":-10.542714,"twenty":-28.285052,"median":-10.45662,"eighty":-8.474871,"marketCap":292244042},{"date":"2025-08-01","current":-9.4,"twenty":-28.006176,"median":-10.433139,"eighty":-8.577715,"marketCap":260567999},{"date":"2025-08-08","current":-9.368693,"twenty":-27.946841,"median":-10.061366,"eighty":-8.607418,"marketCap":259700162},{"date":"2025-08-15","current":-6.668132,"twenty":-27.567096,"median":-9.861782,"eighty":-8.474871,"marketCap":244307015},{"date":"2025-08-22","current":-5.762071,"twenty":-27.424692,"median":-9.803081,"eighty":-8.329026,"marketCap":211110768},{"date":"2025-08-29","current":-5.027748,"twenty":-27.270421,"median":-9.525229,"eighty":-8.145134,"marketCap":184206621},{"date":"2025-09-05","current":-5.027748,"twenty":-27.074615,"median":-9.478268,"eighty":-8.014507,"marketCap":184206621},{"date":"2025-09-12","current":-4.61321,"twenty":-26.629602,"median":-9.396086,"eighty":-7.797069,"marketCap":169018796},{"date":"2025-09-19","current":-6.685898,"twenty":-23.929853,"median":-9.368693,"eighty":-7.515801,"marketCap":244957921},{"date":"2025-09-26","current":-7.503129,"twenty":-17.043362,"median":-9.298251,"eighty":-7.308831,"marketCap":274899634},{"date":"2025-10-03","current":-9.102059,"twenty":-12.821851,"median":-9.210333,"eighty":-7.389343,"marketCap":333481245},{"date":"2025-10-10","current":-9.824539,"twenty":-12.161077,"median":-9.298251,"eighty":-7.460987,"marketCap":359951454},{"date":"2025-10-17","current":-7.876213,"twenty":-12.040618,"median":-9.212156,"eighty":-7.503145,"marketCap":288568676},{"date":"2025-10-24","current":-6.425331,"twenty":-11.978881,"median":-9.149542,"eighty":-7.334887,"marketCap":235411289},{"date":"2025-10-31","current":-6.194375,"twenty":-11.800608,"median":-9.102059,"eighty":-7.096882,"marketCap":226949500},{"date":"2025-11-07","current":-5.844979,"twenty":-11.619352,"median":-9.083015,"eighty":-6.739195,"marketCap":214148333},{"date":"2025-11-14","current":-6.453893,"twenty":-11.527382,"median":-8.978494,"eighty":-6.599437,"marketCap":236457733},{"date":"2025-11-21","current":-4.209833,"twenty":-11.386619,"median":-8.807467,"eighty":-6.451943,"marketCap":205321954},{"date":"2025-11-28","current":-4.455369,"twenty":-11.26527,"median":-8.719067,"eighty":-6.366112,"marketCap":217297254},{"date":"2025-12-05","current":-5.535729,"twenty":-11.176245,"median":-8.71121,"eighty":-6.20385,"marketCap":269988572},{"date":"2025-12-12","current":-6.968768,"twenty":-11.12541,"median":-8.663092,"eighty":-6.182531,"marketCap":339880775},{"date":"2025-12-19","current":-6.111623,"twenty":-11.06083,"median":-8.610671,"eighty":-6.174808,"marketCap":298076093},{"date":"2025-12-26","current":-6.366088,"twenty":-10.989171,"median":-8.599121,"eighty":-6.172233,"marketCap":310486858},{"date":"2026-01-02","current":-5.859391,"twenty":-10.980741,"median":-8.405995,"eighty":-6.111623,"marketCap":285774195},{"date":"2026-01-09","current":-6.477696,"twenty":-10.894921,"median":-8.362013,"eighty":-6.093766,"marketCap":315930176},{"date":"2026-01-16","current":-6.852697,"twenty":-10.894921,"median":-8.218152,"eighty":-6.111623,"marketCap":334219725},{"date":"2026-01-23","current":-6.732161,"twenty":-10.894921,"median":-8.171191,"eighty":-6.111623,"marketCap":328340941},{"date":"2026-01-30","current":-5.959837,"twenty":-10.857352,"median":-8.086731,"eighty":-6.108052,"marketCap":290673181},{"date":"2026-02-06","current":-5.040192,"twenty":-10.779084,"median":-8.030062,"eighty":-6.020346,"marketCap":245820240},{"date":"2026-02-13","current":-5.482157,"twenty":-10.700911,"median":-7.926792,"eighty":-5.956266,"marketCap":267375780},{"date":"2026-02-20","current":-5.540193,"twenty":-10.673027,"median":-7.864204,"eighty":-5.92323,"marketCap":270206305},{"date":"2026-02-27","current":-5.580372,"twenty":-10.643124,"median":-7.834638,"eighty":-5.890776,"marketCap":272165900},{"date":"2026-03-06","current":-2.562507,"twenty":-10.619417,"median":-7.684115,"eighty":-5.801764,"marketCap":124978581},{"date":"2026-03-13","current":-2.34822,"twenty":-10.594371,"median":-7.524231,"eighty":-5.747859,"marketCap":114527410},{"date":"2026-03-20","current":-2.187506,"twenty":-10.558368,"median":-7.450451,"eighty":-5.647336,"marketCap":106689032},{"date":"2026-03-27","current":-1.329623,"twenty":-10.505146,"median":-7.272172,"eighty":-5.612515,"marketCap":76574303},{"date":"2026-04-02","current":-1.549332,"twenty":-10.461316,"median":-7.114571,"eighty":-5.565193,"marketCap":89227607},{"date":"2026-04-10","current":-1.477359,"twenty":-10.383939,"median":-7.072594,"eighty":-5.510729,"marketCap":85082559},{"date":"2026-04-17","current":-1.890261,"twenty":-10.268548,"median":-6.92859,"eighty":-5.336927,"marketCap":108862044},{"date":"2026-04-24","current":-2.034209,"twenty":-10.187377,"median":-6.86609,"eighty":-5.089336,"marketCap":117152140},{"date":"2026-05-01","current":-2.056938,"twenty":-10.153251,"median":-6.792493,"eighty":-4.960237,"marketCap":118461102},{"date":"2026-05-08","current":-1.748556,"twenty":-10.125375,"median":-6.716536,"eighty":-4.705593,"marketCap":122169829},{"date":"2026-05-15","current":-2.101422,"twenty":-10.043581,"median":-6.685898,"eighty":-4.518505,"marketCap":146824271},{"date":"2026-05-22","current":-1.408234,"twenty":-9.951007,"median":-6.641483,"eighty":-4.307154,"marketCap":98391896},{"date":"2026-05-29","current":-1.311437,"twenty":-9.918135,"median":-6.60716,"eighty":-4.188404,"marketCap":91628817},{"date":"2026-06-05","current":-1.230253,"twenty":-9.857086,"median":-6.549693,"eighty":-2.633043,"marketCap":85956556},{"date":"2026-06-12","current":-1.136579,"twenty":-9.835549,"median":-6.495974,"eighty":-2.45715,"marketCap":79411641},{"date":"2026-06-18","current":-1.192783,"twenty":-9.824539,"median":-6.468768,"eighty":-2.34822,"marketCap":83338590},{"date":"2026-06-26","current":-1.57997,"twenty":-9.822648,"median":-6.449019,"eighty":-2.187506,"marketCap":110390908},{"date":"2026-07-02","current":-1.754828,"twenty":-9.791341,"median":-6.425331,"eighty":-2.13573,"marketCap":122608083},{"date":"2026-07-10","current":-1.561235,"twenty":-9.726041,"median":-6.368321,"eighty":-2.087243,"marketCap":109081925},{"date":"2026-07-17","current":-1.976523,"twenty":-9.645626,"median":-6.354268,"eighty":-2.066183,"marketCap":138097717},{"date":"2026-07-24","current":-1.995258,"twenty":-9.546006,"median":-6.285834,"eighty":-2.034209,"marketCap":139406700},{"date":"2026-07-31","current":-1.998381,"twenty":-9.523603,"median":-6.216183,"eighty":-2.015866,"marketCap":139624864},{"date":"2026-08-07","current":-2.279403,"twenty":-9.505361,"median":-6.182531,"eighty":-2.029869,"marketCap":159259610},{"date":"2026-08-14","current":-2.007209,"twenty":-9.48453,"median":-6.16129,"eighty":-2.029869,"marketCap":140281862},{"date":"2026-08-21","current":-1.844378,"twenty":-9.46418,"median":-6.116088,"eighty":-2.0169,"marketCap":128901742},{"date":"2026-08-28","current":-2.072968,"twenty":-9.421915,"median":-6.102695,"eighty":-2.029869,"marketCap":144877680},{"date":"2026-09-04","current":-1.794276,"twenty":-9.395304,"median":-6.053587,"eighty":-1.99756,"marketCap":125400167},{"date":"2026-09-11","current":-1.568817,"twenty":-9.389042,"median":-6.017873,"eighty":-1.978384,"marketCap":109643078}],"updateTime":1789315428348},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AARD\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635035232","title":"熱門話題-FDA對一種罕見病藥物下達臨床暫停令後，Aardvark股價重挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2635035232","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635035232?lang=zh_tw&edition=fundamental","pubTime":"2026-05-15 23:48","pubTimestamp":1778860101,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL4S41S1FX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635267467","title":"FDA對Aardvark治療普拉德-威利綜合徵極度飢餓藥物下達全面臨床暫停令","url":"https://stock-news.laohu8.com/highlight/detail?id=2635267467","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635267467?lang=zh_tw&edition=fundamental","pubTime":"2026-05-15 04:52","pubTimestamp":1778791934,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics周四表示，美国食品药品监督管理局已对其用于治疗与罕见疾病普拉德-威利综合征相关的极度饥饿症状的药物下达了全面临床暂停令，暂停了所有后期临床试验。此前在2月，Aardvark发现健康志愿者服用高于计划剂量的ARD-101药物后出现心脏相关副作用，因此 暂停了 患者招募和给药工作。FDA的临床暂停令适用于ARD-101的所有研究，包括针对普拉德-威利综合征的一项晚期临床试验及扩展研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL4T41R20J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189600944","title":"Aardvark Therapeutics將揭盲Ard-101的HERO與OLE試驗數據以進行評估，並確定該項目的後續計劃","url":"https://stock-news.laohu8.com/highlight/detail?id=1189600944","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189600944?lang=zh_tw&edition=fundamental","pubTime":"2026-05-15 04:03","pubTimestamp":1778789004,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc宣布，公司将揭盲其候选药物Ard-101在HERO试验和开放标签扩展（OLE）试验中的数据，以进行全面评估。此举旨在基于这些关键临床数据，为Ard-101项目的未来发展路径做出决策。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157105953","title":"Aardvark Therapeutics 計劃揭盲HERO與OLE研究數據，為FDA臨床擱置後的前行之路提供指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1157105953","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157105953?lang=zh_tw&edition=fundamental","pubTime":"2026-05-15 04:03","pubTimestamp":1778788980,"startTime":"0","endTime":"0","summary":"在遭遇美国食品药品监督管理局（FDA）的临床搁置后，Aardvark Therapeutics 正计划揭盲其关键研究HERO与开放标签扩展（OLE）试验的数据。此举旨在深入分析现有数据，为确定公司未来的临床开发路径提供关键依据。通过审视这些未公开的详细结果，公司期望能更好地理解监管机构的关切，并据此制定出清晰、可行的后续策略，以推动其研发项目继续向前迈进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622023948","title":"美國研究綜述-亞馬遜、Diamondback Energy、Matador Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2622023948","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622023948?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 16:02","pubTimestamp":1774425725,"startTime":"0","endTime":"0","summary":"美国研究综述-亚马逊、Diamondback Energy、Matador Resources路透3月25日 - 华尔街证券分析师周三调整了对亚马逊、Diamondback Energy 和 Matador Resources 等几家美国上市公司的评级和目标价。要闻  * 亚马逊AMZN.O：摩根大通将目标价从265美元上调至280美元 * Diamondback Energy Inc FANG.O：Gerdes Energy Research将评级从 \"买入 \"下调至 \"中性\"。* National Bank Holdings Corp NBHC.N：Piper Sandler开始覆盖并给予“增持”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4T40D0O3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000KEQY171.SGD","EVGO","BK4598","LU0251142724.SGD","AMZP","AMZW","FANG","AIR","LU1868836757.USD","LU0823434740.USD","AMZU","MKC","LENZ","BZAI","LU2360032135.SGD","MTDR","AFG","FRPT","AARD","AMZY","LU1235294995.USD","AMZN","LU0109391861.USD","AMZD","SGXZ51526630.SGD","LU0098860793.USD","AMZZ","LU0053666078.USD","LU2473716301.USD","BRZE","IE000YTNTUN2.SGD","LU1236620834.HKD","KHC","VITL","LU2362541273.HKD","LU2065171402.SGD","LU2242649171.HKD","AZYY","LU2756315318.SGD","HD","LU1127390331.HKD","USAW.SI","KBH","LU0417517546.SGD","LU0882574139.USD","LU2381873111.SGD","IE00BJJMRX11.SGD","NBHC","LU0354030438.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1132251302","title":"Aardvark Therapeutics與Piper Sandler簽訂股權分銷協議，於2026年3月23日提交SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1132251302","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132251302?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 18:11","pubTimestamp":1774347083,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc. 已与Piper Sandler公司正式签署了一项股权分销协议。该协议的具体条款于2026年3月23日通过美国证券交易委员会（SEC）的文件对外公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621041087","title":"Aardvark 在審查副作用時暫停兩項肥胖症藥物試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2621041087","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621041087?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 05:52","pubTimestamp":1774302743,"startTime":"0","endTime":"0","summary":"路透3月23日 - Aardvark Therapeutics AARD.O周一表示，由于要审查其中一种药物的副作用，它已主动暂停了两项肥胖症试验性联合疗法的中期研究。ARD-201是Aardvark的实验药物ARD-101与默克公司的糖尿病药物MRK.N Januvia的组合。上个月，该公司在一项健康志愿者研究中对 ARD-101 进行安全监测时发现了与心脏有关的副作用。随后，该公司暂停了一项后期试验 ，即在患有罕见遗传性疾病普拉德-威利综合症的患者中测试 ARD-101。Aardvark公司表示，预计将在2026年第二季度提供有关这些药物的进一步更新信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nL4S40B1XI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2168563687.JPY","LU0689472784.USD","IE00BLSP4452.SGD","LU1201861249.SGD","SG9999014898.SGD","LU1093756325.SGD","LU0203347892.USD","IE00BK4W5L77.USD","BK4585","IE0004445239.USD","IE00B1XK9C88.USD","LU1941712264.USD","LU0861579265.USD","LU0266013472.USD","LU2552382215.SGD","LU0320765992.SGD","LU1162221912.USD","SG9999014880.SGD","AARD","IE000M9KFDE8.USD","LU0061475181.USD","LU0683600562.USD","LU2023251221.USD","LU2213496289.HKD","LU0648001328.SGD","SG9999014906.USD","SGXZ51526630.SGD","IE00B2B36J28.USD","LU0234572021.USD","LU2471134952.CNY","LU1989772923.USD","LLII","LU2168564495.EUR","SG9999015986.USD","ELIS","BK4581","LU0787776722.HKD","LU2168564222.USD","LU2324357040.USD","LU2087625088.SGD","LU1145028129.USD","LU0096364046.USD","LU2491049909.HKD","LU2023250843.SGD","LU2456880835.USD","LU0466842654.USD","LU1934455277.USD","LU2089284900.SGD","LU0265550359.USD","LU2756315664.SGD","SG9999015978.USD","GB00BDT5M118.USD","IE0001KFT4U8.USD","IE00BFSS8Q28.SGD","LU2361044949.HKD","SGXZ31699556.SGD","SG9999014567.USD","LU1035775433.USD","LU2023250330.USD","LU2236285917.USD","LU1712237335.SGD","LU0965509283.SGD","LU2750360997.AUD","LU0208291251.USD","LU0823434740.USD","LU2471134523.USD","SG9999014914.USD","LU2462157665.USD","LU2168564065.EUR","LU0882574055.USD","LU0058720904.USD","LU0432979614.USD","LU2896262040.SGD","LU0980610538.SGD","LU2237443622.USD","SGXZ99366536.SGD","LU2264538146.SGD","LU2125154935.USD","LU2265009873.SGD","IE00B775H168.HKD","BK4516","LU1720051017.SGD","SG9999014559.SGD","LU2461242641.AUD","LU2023250504.SGD","LU2089283258.USD","LU1929549753.HKD","LU2112291526.USD","LU1868836757.USD","LU0985320562.USD","LU2237443549.SGD","LU1988902786.USD","LU0823416689.USD","LU1934455194.USD","LU0471298694.HKD","LU2168564149.EUR","LU2237443895.HKD","LU1430594728.SGD","LU1066051811.HKD","LU1974910355.USD","LU2237443465.HKD","SG9999001440.SGD","IE0004445015.USD","LU0882574139.USD","LU2468319806.SGD","SG9999017495.SGD","SG9999001176.SGD","LU0354030438.USD","IE0009355771.USD","LLYZ","IE00BN8TJ469.HKD","LU1983299246.USD","LU0198837287.USD","LU2552382058.USD","IE00B4JS1V06.HKD","LU2361044865.SGD","LU0094547139.USD","LU0965509101.SGD","LU1323610961.USD","IE00BFTCPJ56.SGD","LU0203201768.USD","LU2237438978.USD","LU1868837136.USD","IE00B1BXHZ80.USD","LU0070302665.USD","LU0868494617.USD","LU0114720955.EUR","SG9999013999.USD","LU1064131342.USD","SG9999014575.USD","LU0079474960.USD","LU0786609619.USD","LU1116320737.USD","LU1116320901.HKD","LU1629891620.HKD","LU0820562030.AUD","LU0256863811.USD","LU0203345920.USD","LU0889565916.HKD","LU2602419157.SGD","BK4588","LU0320765646.SGD","LU1804176565.USD","LU2028103732.USD","LU1720051108.HKD","LU0320765489.SGD","LU0868494708.USD","LU2063271972.USD","SG9999002224.SGD","LU1699723380.USD","LLYX","BK4007","LU1066051498.USD","LU1941712348.USD","LU2211815571.USD","LU0353189763.USD","LU1093756168.USD","LU2106854487.HKD","IE0002141913.USD","LU2361045086.USD","ELIL","LU0316494557.USD","LU0640476718.USD","LU0942090050.USD","LU1291159041.SGD","LU0109394709.USD","LU2417539215.USD","IE00BJLML261.HKD","LU0353189680.USD","LU0158827781.USD","SG9999018865.SGD","LU0130517989.USD","LU2089984988.USD","LU0122379950.USD","LU1232071149.USD","LU2360106947.USD","LU2491050154.USD","IE00BLSP4239.USD","SGXZ57979304.SGD","LU0323591593.USD","LU0238689110.USD","IE00BJJMRX11.SGD","LU0225283273.USD","SG9999001176.USD","LU1037948541.HKD","LU1868837300.USD","LU2746668461.USD","SG9999015952.SGD","LU1366192091.USD","LU1623119135.USD","LU0672654240.SGD","LU0471298777.SGD","LU0477156953.USD","LU2111349929.HKD","LU2357305700.SGD","IE00BSNM7G36.USD","SG9999018857.SGD","IE00BJJMRZ35.SGD","LU2471134879.HKD","LU0823434583.USD","LU1989771016.USD","IE00BKDWB100.SGD","BK4599","LU1023059063.AUD","LU1267930730.SGD","IE00BKPKM429.USD","LU0820561818.USD","LU0158827948.USD","LU2271345857.HKD","LU2750360641.GBP","LU1057294990.SGD","IE00B4R5TH58.HKD","IE00BN29S564.USD","LU0320765059.SGD","LU0943347566.SGD","LU0203202063.USD","LU0417517546.SGD","IE00BFSS7M15.SGD","IE00BK4W5M84.HKD","LU2108987350.USD","LU2360032135.SGD","SG9999015358.SGD","LU1066053197.SGD","SGXZ81514606.USD","LU2552382132.HKD","LU1934455863.HKD","LU1551013342.USD","LU2746668974.SGD","LU1280957306.USD","LU0097036916.USD","SG9999002232.USD","SG9999014542.SGD","LU0385154629.USD","LU0965509010.AUD","LU1917777945.USD","LU2125154778.USD","SG9999015945.SGD","LU2756315318.SGD","BK4534","LU1069347547.HKD","LU0820561909.HKD","LU0006306889.USD","BK4533","LU0130102774.USD","LU0211331839.USD","LU1551013425.SGD","LU0109391861.USD","IE0005OL40V9.USD","BK4550","LU0354030511.USD","LU0708995401.HKD","LU1127390331.HKD","LU2491050071.SGD","LU0265550946.USD","LU1035773651.USD","IE00BJJMRY28.SGD","LU1868836914.USD","LU1066051225.USD","LU1814569148.SGD","LU0289739699.SGD","LU1868836591.USD","LU2237443382.USD","LU1037948897.HKD","LU1585245621.USD","LU0098860793.USD","LU1061106388.HKD","LU0106261372.USD","BK4559","LU1548497426.USD","IE00BJT1NW94.SGD","LU0456855351.SGD","IE00BWXC8680.SGD","LU2237443978.SGD","LU0256863902.USD","LU1989772840.SGD","LU2471134796.USD","IE00B7KXQ091.USD","LU0964807845.USD","LU1069344957.HKD","SG9999015341.SGD","LU0210536198.USD","LU1571399168.USD","IE00BBT3K403.USD","LU0965508806.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146815608","title":"Aardvark Therapeutics暫停針對PWS的Ard-101三期HERO及OLE試驗；最新指引預計2026年第二季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1146815608","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146815608?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 04:23","pubTimestamp":1774297410,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics公司宣布，已暂停其候选药物Ard-101用于治疗普瑞德-威利综合征（PWS）的三期HERO临床试验及开放标签扩展（OLE）研究。\n公司表示，预计将在2026年第二季度提供关于该研发项目下一步计划的进一步指导。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125745058","title":"Aardvark Therapeutics暫停Ard-201肥胖症項目，包括力量與體能試驗；進一步指引預計2026年第二季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1125745058","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125745058?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 04:21","pubTimestamp":1774297278,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics已决定暂停其Ard-201肥胖症治疗项目的研发进程，该项目原计划包含针对患者力量与体能改善的临床试验。公司表示，关于该项目的后续发展方向及详细计划，预计将在2026年第二季度提供进一步的明确指引。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}]}}